UPDATE: See June 23, 2020 article here describing the notable changes. See our article here regarding the final October 2020 Guidelines. On November 23, Innovative Medicines Canada and a number of research-based pharmaceutical companies commenced an application for judicial review of the final Guidelines.
The PMPRB has just released revised draft Guidelines operationalizing the amended Patented Medicines Regulations, simultaneously beginning a 30-day consultation period.
An industry webinar on the revised draft Guidelines is scheduled for June 29, 2020 from 1:30 – 4:30pm. A public webinar is scheduled for July 8, 2020 from 1:30 to 4:30pm.
The accompanying backgrounder document is to be released by the PMPRB the week of June 22.
Our more detailed reporting of the substantial changes to the first draft of the Guidelines, which were published in November of 2019, will soon follow (see here).
Should you have any questions on the foregoing, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
New PMPRB Guidelines will not be implemented January 1, 2023
The Patented Medicine Prices Review Board (PMPRB) has advised that the new Guidelines will not be implemented on January 1, 2023, and that the Interim Guidance issued by the Board on August 18, 2022 w...Read More -
Ontario is the latest jurisdiction to implement a biosimilars transition policy
On December 20, 2022, Ontario announced it is implementing a biosimilars transition policy. Starting March 31, 2023, patients receiving coverage from the Ontario Drug Benefit plan for the following in...Read More -
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
Pharmaceutical manufacturers in Canada often enter into Product Listing Agreements (PLA), particularly with public payors, to facilitate their drug being reimbursed. It is common for PLAs to take the ...Read More